Literature DB >> 7811012

Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus.

H Ito1, H Yoshida, M Bogaki-Shonai, T Niga, H Hattori, S Nakamura.   

Abstract

A 6.4-kb DNA fragment containing the DNA gyrase gyrA and gyrB genes was cloned and sequenced from the quinolone-susceptible Staphylococcus aureus type strain ATCC 12600. An expression plasmid was constructed by inserting the cloned genes into the Escherichia coli-S. aureus shuttle vector pAT19, and deletion plasmids carrying only functional gyrA and gyrB genes were derived from this plasmid. An efficient transformation system for S. aureus RN4220 was established by using these plasmids. Quinolone-resistant mutants of S. aureus RN4220 were isolated by three-step selection with quinolones. The first- and second-step mutants were considered to be transport mutants, and the third-step mutants were divided into five groups with respect to their resistance patterns and transformation results with gyrA and gyrB genes. Sequencing analysis of the resulting mutant gyrase genes showed that they had the following point mutations: group 1, Ser-84 (TCA) to Leu (TTA) in GyrA; group 2, Ser-84 (TCA) to Ala (GCA), Ser-85 (TCT) to Pro (CCT), or Glu-88 (GAA) to Lys (AAA) in GyrA; group 3, Asp-437 (GAC) to Asn (AAC) in GyrB; group 4, Arg-458 (CGA) to Gln (CAA) in GyrB; and group 5, Ser-85 (TCT) to Pro (CCT) in GyrA and Asp-437 (GAC) to Asn (AAC) in GyrB. When the gyrA and/or gyrB mutants were transformed with the wild-type gyrA and/or gyrB plasmids, they became quinolone susceptible, but transformants with the plasmids having the same mutations on the gyrA and/or gyrB genes did not confer susceptibility. These results indicate that mutations in both gyrA and gyrB can be responsible for quinolone resistance in S. aureus.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7811012      PMCID: PMC284677          DOI: 10.1128/AAC.38.9.2014

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

1.  Crystal structure of an N-terminal fragment of the DNA gyrase B protein.

Authors:  D B Wigley; G J Davies; E J Dodson; A Maxwell; G Dodson
Journal:  Nature       Date:  1991-06-20       Impact factor: 49.962

2.  In vitro activity of AT-4140 against quinolone- and methicillin-resistant Staphylococcus aureus.

Authors:  T Kojima; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli.

Authors:  S Sreedharan; M Oram; B Jensen; L R Peterson; L M Fisher
Journal:  J Bacteriol       Date:  1990-12       Impact factor: 3.490

4.  Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones.

Authors:  H Yoshida; M Bogaki; S Nakamura; K Ubukata; M Konno
Journal:  J Bacteriol       Date:  1990-12       Impact factor: 3.490

5.  DNA cloning and organization of the Staphylococcus aureus gyrA and gyrB genes: close homology among gyrase proteins and implications for 4-quinolone action and resistance.

Authors:  R Hopewell; M Oram; R Briesewitz; L M Fisher
Journal:  J Bacteriol       Date:  1990-06       Impact factor: 3.490

6.  Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli.

Authors:  H Yoshida; M Bogaki; M Nakamura; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

7.  Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids.

Authors:  H Koga; A Itoh; S Murayama; S Suzue; T Irikura
Journal:  J Med Chem       Date:  1980-12       Impact factor: 7.446

8.  Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.

Authors:  T Miyamoto; J Matsumoto; K Chiba; H Egawa; K Shibamori; A Minamida; Y Nishimura; H Okada; M Kataoka; M Fujita
Journal:  J Med Chem       Date:  1990-06       Impact factor: 7.446

9.  Novel quinolone resistance mutations of the Escherichia coli DNA gyrase A protein: enzymatic analysis of the mutant proteins.

Authors:  P Hallett; A Maxwell
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

10.  Methicillin-resistant strains of Staphylococcus aureus resistant to quinolones.

Authors:  S Schaefler
Journal:  J Clin Microbiol       Date:  1989-02       Impact factor: 5.948

View more
  69 in total

1.  Introduction of a norA promoter region mutation into the chromosome of a fluoroquinolone-susceptible strain of Staphylococcus aureus using plasmid integration.

Authors:  G W Kaatz; S M Seo; T J Foster
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

2.  Characterization of mutations in DNA gyrase and topoisomerase IV Involved in quinolone resistance of Mycoplasma gallisepticum mutants obtained in vitro.

Authors:  A K Reinhardt; C M Bébéar; M Kobisch; I Kempf; A V Gautier-Bouchardon
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

3.  Cloning and sequencing of a novel gene (recG) that affects the quinolone susceptibility of Staphylococcus aureus.

Authors:  T Niga; H Yoshida; H Hattori; S Nakamura; H Ito
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

4.  Genetic determinant of intrinsic quinolone resistance in Fusobacterium canifelinum.

Authors:  Georg Conrads; Diane M Citron; Ellie J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

5.  DNA gyrase and topoisomerase IV mutations associated with fluoroquinolone resistance in Proteus mirabilis.

Authors:  L M Weigel; G J Anderson; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

6.  Quinolone resistance mutations in the GrlB protein of Staphylococcus aureus.

Authors:  M Tanaka; Y Onodera; Y Uchida; K Sato
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci.

Authors:  I González; M Georgiou; F Alcaide; D Balas; J Liñares; A G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

8.  Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.

Authors:  E Y Ng; M Trucksis; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

9.  Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli.

Authors:  P Heisig
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

10.  Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus.

Authors:  T Takenouchi; F Tabata; Y Iwata; H Hanzawa; M Sugawara; S Ohya
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.